Format

Send to

Choose Destination
See comment in PubMed Commons below
Med Clin (Barc). 2013 Sep;141 Suppl 2:20-5. doi: 10.1016/S0025-7753(13)70059-9.

[Limitations of insulin-dependent drugs in the treatment of type 2 diabetes mellitus].

[Article in Spanish]

Author information

1
Servicio de Endocrinología y Nutrición, Hospital Dr. Negrín, Las Palmas de Gran Canaria, España.
2
Servicio de Endocrinología y Nutrición, Hospital Dr. Negrín, Las Palmas de Gran Canaria, España; Departamento de Ciencias Médico-Quirúrgicas, Facultad de Ciencias de la Salud, Universidad de Las Palmas, Las Palmas de Gran Canaria, España. Electronic address: ppablos@dcmq.ulpgc.es.

Abstract

In this study, we review the efficacy and safety limitations of insulin-dependent oral antidiabetic agents. In terms of efficiency, the main drawback of metformin, sulfonylureas, gliptins and -to a lesser extent-glitazones is durability. No drug per se is able to maintain stable blood glucose control for years. Metformin, sulfonylureas and gliptins have demonstrated safety. Experience with the first two drug groups is more extensive. The main adverse effect of metformin is gastrointestinal discomfort. Major concerns related to the use of sulfonylureas are hypoglycemia and weight gain. The use of pioglitazone has been associated with an increased risk of bladder cancer, edema, heart failure, weight gain, and distal bone fractures in postmenopausal women. The most common adverse reactions associated with glucagon-like peptide-1 agonists are gastrointestinal discomfort that sometimes leads to treatment discontinuation.

KEYWORDS:

Antidiabéticos orales; Diabetes tipo 2; Insulin; Insulina; Oral antidiabetics; Type 2 diabetes

PMID:
24444520
DOI:
10.1016/S0025-7753(13)70059-9
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center